pharmaphorum

MAY 17, 2022

As the world and the UK continues its march out of the pandemic’s shadow, the pharmaceutical and life sciences sector has been squarely in the spotlight. In the UK, the Government has often said that we are indebted to the astonishing power of life sciences, especially in the pandemic’s context. The Government has identified the development of a pipeline of highly skilled talent as a key component in the UK economy’s continued growth.

Pharmaceutical Companies 72

Pharmaceutical Companies Pharmaceutical Companies 72

Pharma Mirror

MAY 17, 2022

California, Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers. The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies.

52

52

pharmaphorum

MAY 17, 2022

Strategic coaching is bringing rewards across pharma as the industry adjusts to post-pandemic practices and challenges. Field forces are being realigned, business development re-focussed and digital channels maximised in a new era of sales and engagement. Coaching is now playing a pivotal role in driving better practice and sales performance and it is having an added benefit of boosting employee satisfaction, according to experts.

Communication 72

Communication Hospitals 72

Outsourcing Pharma

MAY 17, 2022

The agency has removed the hold placed on the pharmaceutical companyâs IND for injectable lenacapavir, which is intended for HIV treatment and prevention.

FDA 52

FDA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 17, 2022

BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the London-based research firm. This is the third novel target from the duo’s collaboration identified using the Benevolent Platform across two disease areas – IPF and chronic kidney disease – and subsequently validated and selected for portfolio entry by AstraZeneca.

69

69

Outsourcing Pharma

MAY 17, 2022

The pharmaceutical company reportedly opted to implement the cloud software provider's clinical trial management system to help streamline its processes.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Outsourcing Pharma

MAY 17, 2022

IllumiCare has added the app to its Smart Ribbon point-of-care information tool, enabling providers to connect patients to appropriate clinical studies.

52

52

pharmaphorum

MAY 17, 2022

In this webinar, sponsored by IQVIA, speakers from The Medical Informatics Group at the University Hospital Frankfurt and the Collaboration on Rare Diseases in Medical Informatics project, Germany will discuss the potential of medical informatics in rare disease research and treatment. They will also provide insight into current problems, future challenges and new ideas across the bridge between rare diseases and medical informatics.

Hospitals 52

Hospitals 52

Pharma Times

MAY 17, 2022

Authorisation of the treatment is based on results from the phase 3 trial

55

55

pharmaphorum

MAY 17, 2022

Do you want to be part of the largest gathering of mRNA professionals? The 2 nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. Expect exclusive data from the movers and shakers in mRNA vaccine and therapy development, 75+ world-class speakers, 5 dedicated tracks of content, and 45+ deep-dive case studies. Learn more here: [link].

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

MAY 17, 2022

Team at Imperial College London will expand MELODY study to include immunosuppressed young people

Vaccines 42

Vaccines 42

pharmaphorum

MAY 17, 2022

AstraZeneca has boosted its research capacity by extending its oncology partnership with Proteros biostructures. German pharma firm Proteros specialises in structure-based drug discovery powered by a cutting-edge discovery engine that can unlock complex and technically challenging disease-relevant targets. Proteros’s expertise and tools speed up the research process, particularly at the initial drug discovery and development stages.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52